Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: A retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database
- Fadini G. P.
- Avogaro A.
- Degli Esposti L.
- Russo P.
- Saragoni S.
- Buda S.
- Rosano G.
- Pecorelli S.
- Pani L.
- Martinetti S.
- Mero P.
- Raeli L.
- Migliazza S.
- Dellagiovanna M.
- Cerra C.
- Gambera M.
- Piccinelli R.
- Zambetti M.
- Atzeni F.
- Valsecchi V.
- Deluca P.
- Scopinaro E.
- Moltoni D.
- Pini E.
- Leoni O.
- Oria C.
- Papagni M.
- Nosetti G.
- Caldiroli E.
- Moser V.
- Roni R.
- Polverino A.
- Bovo C.
- Mezzalira L.
- Andretta M.
- Trentin L.
- Palcic S.
- Pettinelli A.
- Arbo A.
- Bertola A.
- Capparoni G.
- Cattaruzzi C.
- Marcuzzo L.
- Rosa F. V.
- Basso B.
- Saglietto M.
- Delucis S.
- Prioli M.
- Filippi R.
- Coccini A.
- Ghia M.
- Sanfelici F.
- Radici S.
- Scanavacca P.
- Campi A.
- Bianchi S.
- Verzola A.
- Morini M.
- Borsari M.
- Danielli A.
- Dal Maso M.
- Marsiglia B.
- Vujovic B.
- Pisani M.
- Bonini P.
- Lena F.
- Aletti P.
- Marcobelli A.
- Sagratella S.
- Fratini S.
- Bartolini F.
- Riccioni G.
- Meneghini A.
- Di Turi R.
- Fano V.
- Blasi A.
- Pagnozzi E.
- Quintavalle G.
- D'Avenia P.
- De Matthaeis M. C.
- Ferrante F.
- Crescenzi S.
- Marziale L.
- Venditti P.
- Bianchi C.
- Senesi I.
- Baci R.
- De Carlo I.
- Lavalle A.
- Trofa G.
- Marcello G.
- Pagliaro C.
- Troncone C.
- Farina G.
- Tari M. G.
- Motola G.
- De Luca F.
- Saltarelli M. L.
- Granieri C.
- Vulnera M.
- Palumbo L.
- La Viola F.
- Florio L.
- De Francesco A. E.
- Costantino D.
- De Francesco A. E.
- Rapisarda F.
- Lazzaro P. L.
- Pastorello M.
- Parlli M.
- Visconti M.
- Uomo I.
- Sanna P.
- Lombardo F.
DOIAbstract
Aims Oral glucose-lowering medications are associated with excess risk of heart failure (HF). Given the absence of comparative data among drug classes, we performed a retrospective study in 32 Health Services of 16 Italian regions accounting for a population of 18 million individuals, to assess the association between HF risk and use of sulphonylureas, DPP-4i, and glitazones. Methods and results We extracted data on patients with type 2 diabetes who initiated treatment with DPP-4i, thiazolidinediones, or sulphonylureas alone or in combination with metformin during an accrual time of 2 years. The endpoint was hospitalization for HF (HHF) occurring after the first 6 months of therapy, and the observation was extended for up to 4 years. A tota...
Add to ORKG